ÂÜÀòÂÒÂ×

Vincent Sandanayaka has a extensive work experience in the pharmaceutical industry. Vincent is currently serving as the Founder, President, and Chief Science Officer (CSO) at Nirogy Therapeutics since January 2022. Prior to this, they held the position of Founder, President, and CEO at Nirogy Therapeutics from November 2019 to January 2022.

Before their involvement with Nirogy Therapeutics, Vincent was the Founder, President, and CEO of Nirogyone Therapeutics from 2014 to 2019.

Vincent'searlier career includes roles at various pharmaceutical companies. Vincent worked as the Senior Director of Chemistry at Karyopharm Therapeutics Inc. from 2009 to 2012. Prior to that, they served as the Director of Chemistry at EPIX Pharmaceuticals from 2007 to 2009.

Vincent also worked at deCODE genetics from 2004 to 2007 as the Associate Director of Medicinal Chemistry. Vincent was the Team Leader-Principal Scientist of Medicinal Chemistry at AstraZeneca from 2001 to 2003.

Vincent'sinitial industry experience began at Pfizer/Wyeth, where they were employed as a Senior Research Scientist in Medicinal Chemistry from 1995 to 2001.

Vincent Sandanayaka pursued their education in the field of Organic Chemistry. From 1988 to 1992, they attended Wayne State University, where they obtained a PhD degree. Following their doctoral studies, they further expanded their knowledge by engaging in a postdoctoral fellowship at Emory University from 1993 to 1995.